Solasodine rhamnosides produced in plants as secondary metabolites, are safe and effective when treating a variety of cancers, including non-melanoma skin cancers. They are cytotoxic against multi-drug resistant tumor cells, stimulate lasting immunity against cancer, are not mutagenic and display anti-mutagenic properties. These antineoplastics, through cellular specific receptor-mediated actions, directly induce apoptosis by triggering extrinsic and intrinsic apoptotic pathways in cancer cells but not normal cells. CuradermBEC5 contains solasodine rhamnosides and is a topical formulation for the treatment of keratoses and non-melanoma skin cancers. The mode of action, together with the selectivity towards cancer cells, with CuradermBEC5 therapy, results in outstanding beneficial outcomes. This study shows graphically and pictorially that CuradermBEC5 seeks and destroys basal cell carcinoma whilst normal skin cells replace the dead cancer cells during therapy, emanating into impressive cosmetic end results. The clinical observations with CuradermBEC5 therapy reveal that initially the lesion size increases over four-fold due to the interaction of CuradermBEC5 with deeper and more lateral tumor cells, followed by a decrease in size, ultimately, resulting in complete elimination of the basal cell carcinoma.
Karia, P.S., Han, J. and Schmults, C.D. (2013) Cutaneous Squamous Cell Carcinoma: Estimated Incidence of Disease, Nodal Metastasis, and Death from Disease in the United States, 2012. Journal of the American Academy of Dermatology, 68, 957-966. http://dx.doi.org/10.1016/j.jaad.2012.11.037
Hartevelt, M.M., Bavink, J.N., Kootte, A.M., Vermeri, B.J. and Vandenbroucke, J.P. (1990) Incidence of Skin Cancer after Renal Transplantation in The Netherlands. Transplantation, 49, 506-509. http://dx.doi.org/10.1097/00007890-199003000-00006
Karagas, M.R., Greenberg, E.R., Spencer, S.K., Stukel, T.A. and Mott, L.A., New Hampshire Skin Cancer Study Group (1999) Increase in Incidence Rates of Basal Cell and Squamous Cell Skin Cancer in New Hampshire, USA. International Journal of Cancer, 81, 555-559. http://dx.doi.org/10.1002/(SICI)1097-0215(19990517)81:4<555::AID-IJC9>3.0.CO;2-R
Cham, B.E. (2011) Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports. International Journal of Clinical Medicine, 2, 473-477. http://dx.doi.org/10.4236/ijcm.2011.24080
Cham, B.E. (2011) Topical CuradermBEC5 Therapy for Periocular Nonmelanoma Skin Cancers: A Review of Clinical Outcomes. International Journal of Clinical Medicine, 4, 233-238. http://dx.doi.org/10.4236/ijcm.2013.45041
Guy, G.P., Machlin, S.R., Ekurieme, D.U. and Yabroff, K.R. (2014) Prevalence and Costs of Skin Cancer Treatment in the US, 2002-2006 and 2007-2011. American Journal of Preventive Medicine, 104, e69-e74.
Cham, B.E., Daunter, B. and Evans, R. (1991) Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides. Cancer Letters, 59, 183-192. http://dx.doi.org/10.1016/0304-3835(91)90140-D
Cham, B.E. and Chase, T.R. (2012) Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells. Do They Also Prime the Immune System Resulting in Long-Term Protection Against Cancer? Planta Medica, 78, 349-353. http://dx.doi.org/10.1055/s-0031-1298149
Liang, C.H., Liu, L.F., Shiu, L.Y., Huang, Y.S., Chang, L.C. and Kuo, K.W. (2004) Action of Solamargine on TNFs and Cisplatin-Resistant Human Lung Cancer Cells. Biochemical and Biophysical Research Communications, 322, 751-758. http://dx.doi.org/10.1016/j.bbrc.2004.07.183
Wang, Y., Gao, J., Gu, G., Li, G., Cui, C., Sun, B. and Lou, H. (2011) In Situ RBL Receptor Visualization and Its Mediated Anticancer Activity for Solasodine Rhamnosides. ChemBioChem, 12, 2418-2420. http://dx.doi.org/10.1002/cbic.201100551
Goldberg, L.H., Landau, J.M., Moody, M.N. and Vergilis-Kalner, I.J. (2011) Treatment of Bowen’s Disease on the Penis with Low Concentration of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen. Dermatologic Surgery, 37, 858-861.
Punjabi, S., Cook, L.J., Kersey, P., Marks, R. and Cerio, R. (2008) Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study. International Journal of Dermatology, 47, 78-82. http://dx.doi.org/10.1111/j.1365-4632.2007.03363.x
Shiu, L.Y., Chang, L.C., Liang, C.H., Huang, Y.S., Sheu, H.M. and Kuo, K.W. (2007) Solamargine Induces Apoptosis and Sensitizes Breast Cancer Cells to Cisplatin. Food and Chemical Toxicology, 45, 2155-2164. http://dx.doi.org/10.1016/j.fct.2007.05.009
Shiu, L.Y., Liang, C.H., Chang, L.C., Sheu, H.M., Tsai, E.M. and Kuo, K.W. (2009) Solamargine Induces Apoptosis and Enhances Susceptibility to Trastazumab and Epirubicin in Breast Cancer Cells with Low or High Expression Levels of HER2/Neu. Bioscience Reports, 29, 35-45. http://dx.doi.org/10.1042/BSR20080028
Sun, L.M., Zhao, Y., Li, X., Yuan, H.Q., Cheng, A.X. and Lou, H.X. (2010) A Lysosomal-Mitochondrial Death Pathway Is Induced by Solamargine in Human K562 Leukemia Cells. Toxicology in Vitro, 24, 1504-1511. http://dx.doi.org/10.1016/j.tiv.2010.07.013
Li, X., Zhao, Y., Wu, W.K.K., Liu, S.S., Cui, M. and Lou, H.X. (2011) Solamargine Induces Apoptosis Associated with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U20S Cells. Life Sciences, 88, 314-321. http://dx.doi.org/10.1016/j.lfs.2010.12.006
Liu, L.F., Liang, C.H., Shiu, L.Y., Lin, W.L., Lin, C.C. and Kuo, K.W. (2004) Action of Solamargine on Human Lung Cancer Cells—Enhancement of the Susceptibility of Cancer Cells to TNFs. FEBS Letters, 577, 67-74. http://dx.doi.org/10.1016/j.febslet.2004.09.064
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal of Biological Sciences, 2, 503-514.
Cham, B.E. and Meares, H.M. (1987) Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man. Cancer Letters, 36, 111-118. http://dx.doi.org/10.1016/0304-3835(87)90081-4
Cham, A., Cham, K.E., Chase, T. and Cham, B.E. (2015) A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity. Relevance to BEC and Solamargine, Example of a Topical Clinical Formulation CuradermBEC5. Journal of Cancer Research and Treatment, 3, 22-27.